VB-201 is under clinical development by Notable Labs and currently in Phase II for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase II drugs for Coronavirus Disease 2019 (COVID-19) have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how VB-201’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VB-201 overview
VB-201 is under development for the treatment of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The drug candidate is administered through oral route. It acts by targeting toll-like receptor (TLR2) and toll-like receptor (TLR4). The drug candidate is a non-oxidative phospholipid (OxPL) analog and is developed based on Lecinoxoid platform technology.
It was also under development for the treatment of vascular inflammation, atherosclerosis, nonalcoholic steatohepatitis, kidney (renal) fibrosis, liver fibrosis, moderate to severe plaque psoriasis, multiple sclerosis, rheumatoid arthritis and ulcerative colitis.
Notable Labs overview
Notable Labs, formerly Vascular Biogenics, operates as a provider of biopharmaceutical products. The company discovers, develops and commercializes gene therapy medicines to treat cancer and inflammatory diseases. Its pipeline products include volasertib, which provides NBL-001; fosciclopirox and a a predictive precision medicine platform. Notable Labs uses its proprietary vascular targeting system technology to enable the systemic administration of gene therapy and improve angiogenic blood vessels. The company carries out its business activities through its subsidiaries in Delaware, the US. Notable Labs is headquartered in Foster City, California, the US.
For a complete picture of VB-201’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
